drugset / Trial / NCT04432233

Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

NCT04432233

NaSingle-groupOpen-labelTreatment

Summary

Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection after active peptic ulcer disease and related complicaitons getting healed, which spent time and money. This study is designed to evaluate the efficacy and safety of intravenous administration of metronidazole, levofloxacin and esomeprazole triple therapy in the treatment of Helicobacter pylori infection combined with peptic ulcer disease related complications.

Timeline

Start
2020-06-15
Primary completion
2021-04-15
Completion
2021-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg Intravenous
Subject Levofloxacin Small molecule 500 mg Intravenous
Subject Metronidazole Small molecule 500 mg Intravenous